Erythroleukemia Medication

Updated: Dec 29, 2015
  • Author: Beata Holkova, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Medication

Medication Summary

Acute erythroleukemia is treated with the same chemotherapeutic regimens as other acute myelogenous leukemias (AMLs), except the M3 variety (acute promyelocytic leukemia [APL]). Preferably, all patients should be treated in a tertiary referral center.

Next:

Antineoplastic agents

Class Summary

Antineoplastic agents are used for induction or consolidation therapy. They include cytarabine, daunorubicin, idarubicin, and mitoxantrone.

Cytarabine

Cytarabine is cell cycle S phase specific. It blocks the progression from G1 to S phase. It is converted intracellularly to the active compound cytarabine-5'-triphosphate, which inhibits DNA polymerase.

Daunorubicin (Cerubidine)

Daunorubicin is an anthracycline antibiotic. It binds to nucleic acids by intercalation between base pairs of DNA, interfering with DNA synthesis. It causes inhibition of DNA topoisomerase II.

Idarubicin (Idamycin PFS)

Idarubicin inhibits cell proliferation by inhibiting DNA and RNA polymerase.

Mitoxantrone (Novantrone)

Idarubicin inhibits cell proliferation by inhibiting DNA and RNA polymerase.

Previous